Every 10-Q that Rallybio Corporation (RLYB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RLYB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLYB filings page.
Rallybio Corporation reported a sharp swing to profitability for the quarter ended June 30, 2026, driven by a $50.0 million termination fee from its previously planned merger with Candid Therapeutics. Net income was $43.7 million, or $7.66 per basic share, despite core operations still generating a $5.7 million operating loss in the quarter and $14.4 million for the first half. Cash and cash equivalents rose to $92.8 million, with total assets of $98.1 million and liabilities of $3.6 million.
Strategically, Rallybio agreed to merge with Avenzo Therapeutics and support a $215.0 million concurrent financing for Avenzo. On a fully diluted, pro forma basis, Avenzo equityholders are expected to own about 56.6% of the combined company, Rallybio holders about 2.8% and new financing investors 40.6%, based on assumed valuations of $15.0 million for Rallybio and $300.0 million for Avenzo. Before closing, Rallybio plans to distribute its net cash to existing securityholders and issue contingent value rights that give them pro rata access to future proceeds from divesting Rallybio’s legacy assets, including milestone and royalty streams from the ENPP1 program sale.
Rallybio Corporation reported a smaller quarterly loss while reinforcing its cash position. For the three months ended March 31, 2026, revenue was $0.2 million, flat year over year, all from a Johnson & Johnson collaboration.
Research and development expenses fell to $2.9 million from $5.7 million, mainly after discontinuing the RLYB212 FNAIT program, while general and administrative costs rose to $6.1 million due largely to legal, professional, and severance charges tied to a terminated merger with Candid Therapeutics. Net loss narrowed to $8.3 million, or $1.46 per share, versus $9.4 million, or $1.69, a year earlier.
As of March 31, 2026, Rallybio held $46.8 million in cash, cash equivalents and marketable securities and expects this to fund operations for more than 12 months. After quarter-end, the company received a $50.0 million termination fee plus $0.4 million of expense reimbursement following Candid’s decision to end their merger agreement.
Rallybio (RLYB) filed its Q3 2025 10‑Q reporting a swing to profitability driven by a joint‑venture sale. The company recorded net income of $16.0 million for the quarter, reflecting $22.5 million of total other income including a $22.4 million gain on the sale of its REV102 JV interest. Core operations remained loss‑making with loss from operations of $6.9 million as R&D fell to $4.1 million and G&A to $3.0 million. Revenue from collaboration and license activities was $212 thousand.
Cash, cash equivalents and marketable securities were $59.3 million as of September 30, 2025. Management states these resources are expected to fund operations for more than 12 months, and elsewhere indicates funding sufficiency through 2027. Weighted‑average shares outstanding were 45,058,591 for the quarter; shares outstanding were 42,243,774 as of October 31, 2025.
The lead asset RLYB116 advanced with a confirmatory PK/PD multiple‑dose study underway; top‑line data are anticipated in Q4 2025. The company discontinued the RLYB212 program in April 2025 and completed a workforce reduction in May 2025 to focus resources on RLYB116 and preclinical programs.